US drug and biologic approvals in 1997

US drug and biologic approvals in 1997

The Prescription Drug User Fee Act of 1992 enhanced review resources for the Food and Drug Administration (FDA). The past two years have seen an unprecedented approval of 92 new drugs and 19 new biologics. Information is provided on the 49 new products approved by the FDA in 1997. Drug Dev. Res. 44:...

Full description

Saved in:
Bibliographic Details
Published in:Drug development research Vol. 44; no. 2-3; pp. 114 - 129
Main Authors: Beary III, John F., Siegfried, John D., Tavares, Renee
Format: Journal Article
Language:English
Published: New York John Wiley & Sons, Inc 01-06-1998
Wiley-Liss
Subjects:
Biological and medical sciences
Food and Drug Administration (FDA)
General pharmacology
Medical sciences
new drug and biologic approvals
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
therapeutics
United States
North America
America
Marketing authorization
Drug
1997
Chemotherapy
New product
Biological treatment
Pharmaceutical industry
Food and Drug Administration
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Prescription Drug User Fee Act of 1992 enhanced review resources for the Food and Drug Administration (FDA). The past two years have seen an unprecedented approval of 92 new drugs and 19 new biologics. Information is provided on the 49 new products approved by the FDA in 1997. Drug Dev. Res. 44:114–129, 1998. © 1998 Wiley‐Liss, Inc.
Bibliography:istex:36E33CB1A543A302BFC7158BBA18A36EBC93BD65
ark:/67375/WNG-1BZW5TZM-2
ArticleID:DDR9
ISSN:0272-4391
1098-2299
DOI:10.1002/(SICI)1098-2299(199806/07)44:2/3<114::AID-DDR9>3.0.CO;2-P